AR009457A1 - HETERO-CYCLIC METALOPROTEASE INHIBITORS AND USE OF THEM TO PREPARE PHARMACEUTICAL COMPOSITIONS. - Google Patents
HETERO-CYCLIC METALOPROTEASE INHIBITORS AND USE OF THEM TO PREPARE PHARMACEUTICAL COMPOSITIONS.Info
- Publication number
- AR009457A1 AR009457A1 ARP970103902A ARP970103902A AR009457A1 AR 009457 A1 AR009457 A1 AR 009457A1 AR P970103902 A ARP970103902 A AR P970103902A AR P970103902 A ARP970103902 A AR P970103902A AR 009457 A1 AR009457 A1 AR 009457A1
- Authority
- AR
- Argentina
- Prior art keywords
- hetero
- cyclic
- pharmaceutical compositions
- refers
- prepare pharmaceutical
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos utiles como inhibidores de metaloproteasas, y los cuales son eficaces en el tratamiento de los síntomas caracterizados por el exceso deactividad de estas enzimas. En particular, se refiere a un compuesto que posee una estructura deac uerdo a la formula (I). Los sustituyentes son tal como sedefinen en la memoria. Se refiere además a varios otros procesos que toman ventajas de las propiedades unicas de estos compuestos. Por lo tanto serefiere a los compuestos formula (I)conju gados con soportes solidos. Estas combinaciones pueden ser utilizadas como reactivos de afinidad para lapurificacion de la metaloproteasa deseada.Compounds useful as metalloprotease inhibitors, and which are effective in treating symptoms characterized by excess activity of these enzymes. In particular, it refers to a compound that has a structure according to formula (I). Substituents are as defined in the specification. It also refers to several other processes that take advantage of the unique properties of these compounds. Therefore it refers to the compounds formula (I) conjugated with solid supports. These combinations can be used as affinity reagents for purification of the desired metalloprotease.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2484696P | 1996-08-28 | 1996-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR009457A1 true AR009457A1 (en) | 2000-04-26 |
Family
ID=21822698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970103902A AR009457A1 (en) | 1996-08-28 | 1997-08-27 | HETERO-CYCLIC METALOPROTEASE INHIBITORS AND USE OF THEM TO PREPARE PHARMACEUTICAL COMPOSITIONS. |
Country Status (25)
Country | Link |
---|---|
US (2) | US6121258A (en) |
EP (1) | EP0923561B1 (en) |
JP (1) | JP3347331B2 (en) |
KR (1) | KR20000035920A (en) |
CN (1) | CN1228772A (en) |
AR (1) | AR009457A1 (en) |
AT (1) | ATE226573T1 (en) |
AU (1) | AU734834B2 (en) |
BR (1) | BR9712085A (en) |
CA (1) | CA2263917A1 (en) |
CO (1) | CO4920240A1 (en) |
CZ (1) | CZ62699A3 (en) |
DE (1) | DE69716615T2 (en) |
DK (1) | DK0923561T3 (en) |
HU (1) | HUP0000210A3 (en) |
ID (1) | ID18416A (en) |
IL (1) | IL128664A (en) |
NO (1) | NO314934B1 (en) |
NZ (1) | NZ334254A (en) |
PE (1) | PE2599A1 (en) |
PL (1) | PL331795A1 (en) |
SK (1) | SK25799A3 (en) |
TR (1) | TR199900382T2 (en) |
WO (1) | WO1998008823A1 (en) |
ZA (1) | ZA977696B (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69716934T2 (en) * | 1996-08-28 | 2003-07-31 | Procter & Gamble | 1,3-DIHETEROCYCLIC METALOPROTEASE INHIBITORS |
KR100352316B1 (en) | 1997-07-31 | 2002-09-12 | 더 프록터 앤드 갬블 캄파니 | Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors |
NZ505968A (en) | 1998-02-04 | 2003-03-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases |
US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
US6846478B1 (en) | 1998-02-27 | 2005-01-25 | The Procter & Gamble Company | Promoting whole body health |
AU1708099A (en) | 1998-06-03 | 1999-12-20 | Amgen, Inc. | N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres |
US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
US6333340B1 (en) * | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
US6509337B1 (en) * | 1998-09-17 | 2003-01-21 | Pfizer Inc. | Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors |
US6300341B1 (en) | 1998-09-30 | 2001-10-09 | The Procter & Gamble Co. | 2-substituted heterocyclic sulfonamides |
WO2000018358A2 (en) * | 1998-09-30 | 2000-04-06 | The Procter & Gamble Company | Method of treating hair loss using ketoamides |
US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
KR20010086073A (en) * | 1998-12-02 | 2001-09-07 | 데이비드 존 우드 | Methods and Compositions for Restoring Conformational Stability of a Protein of the p53 Family |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6544984B1 (en) | 1999-01-27 | 2003-04-08 | American Cyanamid Company | 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
AR022423A1 (en) * | 1999-01-27 | 2002-09-04 | American Cyanamid Co | COMPOUNDS DERIVED FROM ACIDS 2,3,4,5-TETRAHIDRO-1H- [1,4] BENZODIAZEPINA-3-HYDROXAMICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
BR0009244A (en) | 1999-03-03 | 2002-04-16 | Procter & Gamble | Diheter metalloprotease inhibitors replaced |
NZ513831A (en) | 1999-03-03 | 2001-09-28 | Procter & Gamble | Alkenyl- and alkynyl-containing metalloprotease inhibitors |
US6967197B2 (en) * | 2000-02-21 | 2005-11-22 | Fujisawa Pharmaceutical Co., Ltd. | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
DE60134854D1 (en) | 2000-06-30 | 2008-08-28 | Procter & Gamble | ORAL PREPARATIONS CONTAINING HOST RESPONSE MODULATING ACTIVE SUBSTANCES |
US8283135B2 (en) | 2000-06-30 | 2012-10-09 | The Procter & Gamble Company | Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
MXPA03011095A (en) * | 2001-05-29 | 2005-04-28 | Guilford Pharm Inc | Method for treating nerve injury caused by surgery. |
EP1440057A1 (en) | 2001-11-01 | 2004-07-28 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
CA2526222A1 (en) * | 2003-05-16 | 2004-12-02 | Arriva Pharmaceuticals, Inc. | Treatment of respiratory disease associated with matrix metalloprotease inhibitors |
EP1691852A2 (en) * | 2003-11-10 | 2006-08-23 | Angiotech International AG | Medical implants and fibrosis-inducing agents |
JP4777738B2 (en) * | 2004-10-14 | 2011-09-21 | 株式会社 資生堂 | Prevention or improvement of wrinkles by ADAM activity inhibitors |
JP2007119444A (en) * | 2005-09-29 | 2007-05-17 | Shiseido Co Ltd | Wrinkling prevention or mitigation with adam inhibitor |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601368D0 (en) * | 1986-01-21 | 1986-02-26 | Ici America Inc | Hydroxamic acids |
DK77487A (en) * | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | hydroxylamine |
FR2609289B1 (en) * | 1987-01-06 | 1991-03-29 | Bellon Labor Sa Roger | NOVEL COMPOUNDS HAVING ACTIVITY OF COLLAGENASE INHIBITORS, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
GB8919251D0 (en) * | 1989-08-24 | 1989-10-04 | British Bio Technology | Compounds |
DE4011172A1 (en) * | 1990-04-06 | 1991-10-10 | Degussa | COMPOUNDS FOR CONTROLLING PLANT DISEASES |
US5189178A (en) * | 1990-11-21 | 1993-02-23 | Galardy Richard E | Matrix metalloprotease inhibitors |
US5183900A (en) * | 1990-11-21 | 1993-02-02 | Galardy Richard E | Matrix metalloprotease inhibitors |
GB9102635D0 (en) * | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
GB9107368D0 (en) * | 1991-04-08 | 1991-05-22 | Smithkline Beecham Plc | Novel compounds |
IL98681A (en) * | 1991-06-30 | 1997-06-10 | Yeda Rehovot And Dev Company L | Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives |
DE4127842A1 (en) * | 1991-08-22 | 1993-02-25 | Rhone Poulenc Rorer Gmbh | New 5-(omega-arylalkyl)-2-thienyl alkanoic acid derivs. as LTB inhibitors - for treating eczema, psoriasis, acne, arthritis, asthma, rhinitis and inflammatory skin disorders |
JPH05125029A (en) * | 1991-11-06 | 1993-05-21 | Yamanouchi Pharmaceut Co Ltd | New amide compound or its salt |
WO1993020047A1 (en) * | 1992-04-07 | 1993-10-14 | British Bio-Technology Limited | Hydroxamic acid based collagenase and cytokine inhibitors |
EP0639982A1 (en) * | 1992-05-01 | 1995-03-01 | British Biotech Pharmaceuticals Limited | Use of mmp inhibitors |
AU666727B2 (en) * | 1992-06-25 | 1996-02-22 | F. Hoffmann-La Roche Ag | Hydroxamic acid derivatives |
GB9215665D0 (en) * | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
GB9223904D0 (en) * | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB9411598D0 (en) * | 1994-06-09 | 1994-08-03 | Hoffmann La Roche | Hydroxamic acid derivatives |
CN1151157A (en) * | 1994-06-22 | 1997-06-04 | 英国生物技术药物有限公司 | Metalloproteinase inhibitors |
WO1996033172A1 (en) * | 1995-04-20 | 1996-10-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
CN1131215C (en) * | 1995-11-13 | 2003-12-17 | 赫彻斯特股份公司 | Cyclic and heterocyclic n-substituted 'alpha'-iminohydroxamic acid carboxylic acids |
AU725831C (en) * | 1995-12-08 | 2002-10-17 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
EP0780386B1 (en) * | 1995-12-20 | 2002-10-02 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
-
1997
- 1997-08-22 DK DK97939443T patent/DK0923561T3/en active
- 1997-08-22 WO PCT/US1997/014553 patent/WO1998008823A1/en not_active Application Discontinuation
- 1997-08-22 PL PL97331795A patent/PL331795A1/en unknown
- 1997-08-22 AU AU41530/97A patent/AU734834B2/en not_active Ceased
- 1997-08-22 HU HU0000210A patent/HUP0000210A3/en unknown
- 1997-08-22 IL IL12866497A patent/IL128664A/en not_active IP Right Cessation
- 1997-08-22 CN CN97197544A patent/CN1228772A/en active Pending
- 1997-08-22 BR BR9712085-5A patent/BR9712085A/en unknown
- 1997-08-22 KR KR1019997001656A patent/KR20000035920A/en not_active Application Discontinuation
- 1997-08-22 CA CA002263917A patent/CA2263917A1/en not_active Abandoned
- 1997-08-22 CZ CZ99626A patent/CZ62699A3/en unknown
- 1997-08-22 EP EP97939443A patent/EP0923561B1/en not_active Expired - Lifetime
- 1997-08-22 SK SK257-99A patent/SK25799A3/en unknown
- 1997-08-22 AT AT97939443T patent/ATE226573T1/en not_active IP Right Cessation
- 1997-08-22 NZ NZ334254A patent/NZ334254A/en unknown
- 1997-08-22 DE DE69716615T patent/DE69716615T2/en not_active Expired - Fee Related
- 1997-08-22 TR TR1999/00382T patent/TR199900382T2/en unknown
- 1997-08-22 JP JP51171398A patent/JP3347331B2/en not_active Expired - Fee Related
- 1997-08-26 US US08/918,957 patent/US6121258A/en not_active Expired - Fee Related
- 1997-08-27 CO CO97049501A patent/CO4920240A1/en unknown
- 1997-08-27 AR ARP970103902A patent/AR009457A1/en unknown
- 1997-08-27 ZA ZA9707696A patent/ZA977696B/en unknown
- 1997-08-28 ID IDP972993A patent/ID18416A/en unknown
- 1997-08-28 PE PE1997000767A patent/PE2599A1/en not_active Application Discontinuation
-
1999
- 1999-02-18 NO NO19990759A patent/NO314934B1/en not_active IP Right Cessation
-
2000
- 2000-03-01 US US09/516,726 patent/US6399598B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6399598B1 (en) | 2002-06-04 |
HUP0000210A3 (en) | 2001-07-30 |
NO990759L (en) | 1999-04-27 |
JP2000516953A (en) | 2000-12-19 |
US6121258A (en) | 2000-09-19 |
EP0923561B1 (en) | 2002-10-23 |
PL331795A1 (en) | 1999-08-02 |
DK0923561T3 (en) | 2003-02-24 |
DE69716615T2 (en) | 2003-06-18 |
ID18416A (en) | 1998-04-09 |
WO1998008823A1 (en) | 1998-03-05 |
KR20000035920A (en) | 2000-06-26 |
AU734834B2 (en) | 2001-06-21 |
HUP0000210A2 (en) | 2001-04-28 |
EP0923561A1 (en) | 1999-06-23 |
SK25799A3 (en) | 1999-12-10 |
CN1228772A (en) | 1999-09-15 |
IL128664A (en) | 2003-07-06 |
DE69716615D1 (en) | 2002-11-28 |
NO314934B1 (en) | 2003-06-16 |
BR9712085A (en) | 2000-10-24 |
PE2599A1 (en) | 1999-03-03 |
IL128664A0 (en) | 2000-01-31 |
JP3347331B2 (en) | 2002-11-20 |
CZ62699A3 (en) | 1999-07-14 |
CA2263917A1 (en) | 1998-03-05 |
NZ334254A (en) | 2000-11-24 |
AU4153097A (en) | 1998-03-19 |
NO990759D0 (en) | 1999-02-18 |
ATE226573T1 (en) | 2002-11-15 |
CO4920240A1 (en) | 2000-05-29 |
ZA977696B (en) | 1998-02-23 |
TR199900382T2 (en) | 1999-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR009457A1 (en) | HETERO-CYCLIC METALOPROTEASE INHIBITORS AND USE OF THEM TO PREPARE PHARMACEUTICAL COMPOSITIONS. | |
PA8468401A1 (en) | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | |
PT927161E (en) | REPLACED CYCLIC AMINES METALOPROTEASE INHIBITORS | |
GT199900217A (en) | COMPOUNDS USED IN THE TREATMENT OF INFLAMMATORY MATTERS. | |
AR008861A1 (en) | ARALQUILO AND ARALQUILEDENO LETAMIC AND IMIDA LACTAM COMPOUNDS, INTERMEDIARY COMPOUNDS FOR YOUR SYNTHESIS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
CR7387A (en) | NEW ACTIVE HETEROCICLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASAS | |
AR011116A1 (en) | N-HYDROXY-BETA-SULFONIL PROPIONAMIDE DERIVED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING IT | |
PA8541601A1 (en) | NEW SPIROCICLIC DERIVATIVES AND ITS USE AS INHIBITORS OF PHOSPHODIESTERASA-7. | |
UY26058A1 (en) | USEFUL COMPOUNDS AS ANTI-INFLAMMATORY LAW 17,164 ART. 127 | |
BR0112786A (en) | Non-Steroidal Inhibitors of Inflammation | |
EA199900532A1 (en) | NITROGEN OXIDE SYNTHASE INHIBITORS | |
ES2183937T3 (en) | INHIBITORS OF THE CELL ADHESION. | |
AR002267A1 (en) | IMIDAZOLE COMPOUNDS USEFUL FOR THE TREATMENT OF PATHOLOGIES MEDIATED BY CYTOKINES; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; PROCESS TO PREPARE SUCH COMPOUNDS; USE OF THE SAME TO PREPARE SUCH COMPOSITIONS; INTERMEDIATE COMPOUNDS AND PROCESSES FOR ITS PREPARATION. | |
CR6393A (en) | CCR5 MODULATORS | |
HN1998000035A (en) | NEW DERIVATIVES OF HEXANOIC ACID | |
ES2183331T3 (en) | SULFAMIDA-METALOPROTEASA INHIBITORS. | |
UY26092A1 (en) | USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES | |
BR9806296B1 (en) | sulfonic acid compounds, mixture, composition and use thereof. | |
CO4940451A1 (en) | DERIVATIVES OF BARBITURIC ACID WITH ANTIMETASTIC AND ANTITUMORAL ACTIVITY | |
UY26199A1 (en) | NEW BENZENE DERIVATIVES, A PROCEDURE FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
AR021596A1 (en) | COMPOUNDS THAT INHIBIT THE PROCOLAGENO C-PROTEINASE. | |
MX9305364A (en) | RETROVIRAL PROTEASE INHIBITING COMPOUNDS, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM. | |
ES2060818T3 (en) | DERIVATIVES OF INDOL, BENZOFURANO AND BENZOTIOFENO SUBSTITUTED AS INHIBITORS OF 5-LIPOOXIGENASA. | |
YU11401A (en) | Nimesulide containing topical pharmaceutical compositions | |
MX9207557A (en) | DERIVATIVES OF ACIDS BENZOFURANIL- AND TIOFENILMETILTIO-ALCANOCARBOXILICOS, PROCEDURE FOR ITS PREPARATION AND MEDICINES THAT CONTAIN THEM. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |